Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
- 1 February 1986
- journal article
- clinical trial
- Published by Wiley
- Vol. 21 (S1) , 77S-81S
- https://doi.org/10.1111/j.1365-2125.1986.tb02857.x
Abstract
The effects on plasma lipids and apoproteins A-I and B of oral administration of doxazosin and atenolol over a 20-week period were studied in 42 patients with mild to moderate essential hypertension. Total plasma cholesterol decreased by 8.9% (P less than 0.01) and LDL cholesterol by 16.9% (P less than 0.01) after 20 weeks' treatment with doxazosin. Total HDL cholesterol and HDL2 cholesterol concentrations increased slightly during doxazosin treatment and the increase in HDL2 level at 4 weeks was statistically significant (P less than 0.05). At 20 weeks, the levels of total HDL cholesterol and HDL2 were significantly (P less than 0.05) lower with atenolol than with doxazosin. The ratio HDL/total cholesterol increased during doxazosin treatment (P less than 0.05 at 4, 12 and 20 weeks). The HDL/total cholesterol ratio was significantly higher after 20 weeks with doxazosin than with atenolol (P less than 0.05). The levels of VLDL cholesterol and triglycerides increased significantly (P less than 0.01) during atenolol treatment. The concentrations of apoproteins A-I and B did not change significantly during treatment with doxazosin or with atenolol but at 20 weeks the ratio of apo A-I to apo B was significantly (P less than 0.05) lower with atenolol than with doxazosin. On the basis of these results, doxazosin would seem to have significant favourable effects on the serum lipid profile.Keywords
This publication has 18 references indexed in Scilit:
- A long‐term double‐blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.British Journal of Clinical Pharmacology, 1986
- Effect of atenolol on plasma HDL cholesterol subfractionsAtherosclerosis, 1984
- Effect of pindolol on serum lipids and lipid metabolizing enzymes.Published by Wiley ,1982
- Discriminative value of lipids and apoproteins in coronary heart diseaseAtherosclerosis, 1982
- EFFECT OF PROPRANOLOL AND PRAZOSIN ON BLOOD LIPIDSThe Lancet, 1980
- Metabolic consequences of atenolol and propranolol in treatment of essential hypertension.BMJ, 1979
- High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study.BMJ, 1978
- Beta-blockers and plasma triglycerides.BMJ, 1978
- High density lipoprotein as a protective factor against coronary heart diseaseThe American Journal of Medicine, 1977
- INCREASE IN SERUM-LIPIDS DURING TREATMENT OF HYPERTENSION WITH CHLORTHALIDONEThe Lancet, 1976